ClinicalTrials.gg
CompletedNCT02943993ETNA-VTEUpdated Apr 1, 2025Results posted

Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe

An observational study in Venous Thromboembolism, sponsored by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-01.

Sponsored by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (part of Daiichi Sankyo) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,809
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Venous Thromboembolism by Daiichi Sankyo — none open to participants now, none under way, none of them phase 3. Venous Thromboembolism · Daiichi Sankyo.

Started
2016
with 2 others
Observational
3 of 16
none open now
Registered
14th of 16
by date

Among the 16 studies in Venous Thromboembolism by Daiichi Sankyo, this one is one of 3 that started in 2016, is one of 3 observational ones, and was the 14th registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

None of the 16 studies in Venous Thromboembolism by Daiichi Sankyo is open now. The open studies under Venous Thromboembolism, anywhere →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Venous Thromboembolism by Daiichi Sankyo as a file.
02

Study summary

According to current guidelines, duration of anticoagulant treatment after a venous thromboembolic event varies from 3 months to indefinite treatment depending on the estimated risks of venous thromboembolism (VTE) recurrence and bleeding. Current data for edoxaban are limited to a maximum treatment duration of 12 months (Hokusai-VTE; N Engl J Med. 2013; 369:1406-15).

Therefore, this study aims to gather further insight into efficacy (i.e. symptomatic recurrent VTE) and safety (i.e. bleeding events, liver adverse events, all-cause mortality and other drug related adverse events) of extended treatment with edoxaban up to 18 months in an unselected patient population in routine clinical practice.

Read the detailed description

Real-world evidence data in routine clinical practice use of edoxaban up to 18 months will be collected in 2,700 patients, treated by specialized as well as non-specialized physicians in hospitals and office based centres in 8 European countries. Patients from different countries and care settings (primary care and secondary care, different specialties) will be enrolled in this post-authorization safety study. Documentation of baseline and follow up information at 1, 3, 6, 12, and 18 months (only when available) will be collected. In addition, recurrence of symptomatic VTE and death will be captured retrospectively at time point of Last Patient Out per country.

Patients who discontinue permanently edoxaban during the observational period will be followed up according to the same scheme.

03

Conditions studied

  • Venous Thromboembolism

Keywords

  • Post-Authorisation Safety Study
  • Real World Evidence
  • Edoxaban
  • Efficacy/Safety
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients with established initial or recurrent acute symptomatic VTE (distal or proximal deep vein thrombosis/pulmonary embolism) treated with edoxaban according to the Summary of Product Characteristics (SmPC). To ensure that the physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban. Patients must have provided written informed consent for participation in the study (ICF) and should not participate simultaneously in any interventional study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Established acute initial or recurrent VTE
  • Clinical decision for treatment with edoxaban is made at the time of enrollment
  • Written for participation in the study (ICF)
  • Not simultaneously participating in any interventional study

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,809 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients treated with Edoxaban

    Patients with established initial or recurrent acute symptomatic VTE treated with edoxaban according to the Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.

    Drug: Edoxaban

Interventions

  • Prescribed according to approved label

    Also known as: Lixiana

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - Overall

    Descriptive statistics were used to report the number of participants with at least 1 symptomatic VTE recurrence. Recurrent VTE events were based on adjudicated events. For the overall symptomatic VTE, precentage of participants (including 95% confidence intervals) were calculated.

    Time frame: Baseline up to end of observation period (18 months)

  2. Number of Participants With Bleeding Events (Adjudicated) While On Edoxaban Treatment

    Descriptive statistics were used to report the number of participants with bleeding events. For the analysis of bleeding events, absolute number of participants were calculated.

    Time frame: Baseline up to end of observation period (18 months)

Secondary outcomes

  1. Percentage of Participants Experiencing At Least 1 Real World Safety Event - Overall

    Descriptive statistics were used to report the number of participants experiencing recurrent VTE and at least 1 real world safety event. VTE recurrence data were reported by recurrent deep vein thrombosis (DVT), recurrent pulmonary embolism (PE) with DVT, and recurrent PE only. Recurrent VTE events were based on adjudicated events. Real world safety events included all-cause death, cardiovascular (CV)-related death, VTE-related death, stroke, systemic embolic event, and hospitalization related to CV. For recurrent VTE and real world safety events, absolute and relative frequencies (including 95% confidence intervals) were calculated.

    Time frame: Baseline up to end of observation period (18 months)

  2. Percentage of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - On Edoxaban Treatment

    Descriptive statistics were used to report the number of participants with overall symptomatic VTE recurrence. VTE recurrence data were further reported by recurrent deep venous thrombosis (DVT), recurrent pulmonary embolism (PE) with deep venous thrombosis (DVT), and recurrent PE only. Recurrent VTE events were based on adjudicated events. For symptomatic VTE recurrence, percentage of participants (95% confidence intervals) were calculated.

    Time frame: Baseline up to end of observation period (18 months)

  3. Total Number of Venous Thromboembolism Recurrences By Type - Overall

    Descriptive statistics were used to describe the number of VTE events reported by the patient. For VTE recurrences, absolute number of VTE events were calculated.

    Time frame: Baseline up to end of observation period (18 months)

  4. Duration of Venous Thromboembolism Recurrences, by Type - Overall

    Descriptive statistics were used to assess the duration of VTE events reported by the patient. For VTE recurrences, median duration of VTE events (interquartile range) were calculated.

    Time frame: Baseline up to end of observation period (18 months)

  5. Total Number of Venous Thromboembolism Recurrences (On Edoxaban Treatment)

    Descriptive statistics were used to assess the number of recurrent VTE events reported by the patient. For VTE recurrences, absolute number of VTE recurrences were calculated.

    Time frame: Baseline up to end of observation period (18 months)

  6. Duration of Venous Thromboembolism Events (On Edoxaban Treatment)

    Descriptive statistics were used to assess the duration of VTE events reported by the patient. For VTE events, median duration of VTE events (interquartile range) were calculated.

    Time frame: Baseline up to end of observation period (18 months)

  7. Number of Participants With Risk Factors for Thromboembolic Events at Baseline

    Descriptive statistics were used to assess the number of participants with risk factors for thromboembolic events. For risk factors for thromboembolic events, absolute number of participants with risk factors (percentage) were calculated.

    Time frame: at Baseline

  8. Duration of Edoxaban Treatment

    Descriptive statistics were used to report the duration of edoxaban treatment.

    Time frame: Baseline up to end of observational period (18 months)

  9. Number of Stroke Events

    Descriptive statistics were used to report the number of stroke events. For stroke events, absolute number of stroke events were calculated.

    Time frame: Baseline up to end of observation period (18 months)

  10. Number of Systemic Embolic Events - Overall

    Descriptive statistics were used to report the number of systemic embolic events (SEE). For SEE, absolute SEEs were calculated.

    Time frame: Baseline up to end of observation period (18 months)

  11. Overview of Participants With Adverse Drug Reactions

    Descriptive statistics were used to report an overview of participants with adverse drug reactions (ADR). ADRs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1.

    Time frame: Baseline up to end of observation period (18 months)

  12. Number of Participants With Adverse Drug Reactions by Preferred Term (≥0.2%)

    Adverse drug reactions were reported and coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1.

    Time frame: Baseline up to end of observational period (18 months)

  13. Number of Participants With Pre-defined Adverse Drug Reactions

    Descriptive statistics were used to report the number of participants with pre-defined adverse drug reactions (ADR). ADRs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1.

    Time frame: Baseline up to end of observation period (18 months)

07

Results

Posted May 2, 2022

Participant flow

A total of 2809 participants were included in the All Documented Patient Set defined as participants with a signed ICF and trustworthy data at sites in Germany, Austria, Switzerland, Belgium, The Netherlands, United Kingdom, Ireland, and Italy; a total of 2655 participants were included in the Baseline Analysis Set and a total of 2644 participants were included in the Full Analysis Set.

Participant flow — Overall Study
MilestoneETNA-VTE
Started2655
Full analysis set2644
Completed2325
Not completed330
Withdrew: Withdrawal by subject52
Withdrew: Transfer to another institution6
Withdrew: Lost to follow-up135
Withdrew: Death98
Withdrew: Other reason for premature termination32
Withdrew: Missing reason for termination7

Outcome measures

PrimaryPercentage of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - Overall

Descriptive statistics were used to report the number of participants with at least 1 symptomatic VTE recurrence. Recurrent VTE events were based on adjudicated events. For the overall symptomatic VTE, precentage of participants (including 95% confidence intervals) were calculated.

Time frame:
Baseline up to end of observation period (18 months)
Reported as:
Number · Percentage of VTE recurrence
Percentage of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - Overall
Percentage of VTE recurrenceETNA-VTE
Percentage of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - Overall3.8 (3.09 to 4.58)
PrimaryNumber of Participants With Bleeding Events (Adjudicated) While On Edoxaban Treatment

Descriptive statistics were used to report the number of participants with bleeding events. For the analysis of bleeding events, absolute number of participants were calculated.

Time frame:
Baseline up to end of observation period (18 months)
Reported as:
Number · participants
Number of Participants With Bleeding Events (Adjudicated) While On Edoxaban Treatment
participantsETNA-VTE
Participants with any bleeding events304 (10.31 to 12.78)
At least 1 major bleeding event38 (0.99 to 1.92)
Clinically relevant non-major bleeding event82
Minor300
Gastrointestinal bleeding event77
Epidural or subdural haematoma bleeding event4
Intra-ocular bleeding event5
Intra-articular bleeding event3
Pleural bleeding event1
Other bleeding event319
Spontaneous bleeding287
Provoked bleeding115
Unknown bleeding18
SecondaryPercentage of Participants Experiencing At Least 1 Real World Safety Event - Overall

Descriptive statistics were used to report the number of participants experiencing recurrent VTE and at least 1 real world safety event. VTE recurrence data were reported by recurrent deep vein thrombosis (DVT), recurrent pulmonary embolism (PE) with DVT, and recurrent PE only. Recurrent VTE events were based on adjudicated events. Real world safety events included all-cause death, cardiovascular (CV)-related death, VTE-related death, stroke, systemic embolic event, and hospitalization related to CV. For recurrent VTE and real world safety events, absolute and relative frequencies (including 95% confidence intervals) were calculated.

Time frame:
Baseline up to end of observation period (18 months)
Reported as:
Number · Percentage of real world safety events
Percentage of Participants Experiencing At Least 1 Real World Safety Event - Overall
Percentage of real world safety eventsETNA-VTE
Recurrent DVT only2.3 (1.77 to 2.95)
Recurrent PE with DVT0.3 (0.11 to 0.54)
Recurrent PE only1.2 (0.80 to 1.66)
All-cause death3.6 (2.92 to 4.37)
Cardiovascular-related death0.9 (0.55 to 1.30)
Venous thromboembolism-related death0 (0 to 0.21)
Stroke1.0 (0.64 to 1.44)
Systemic embolic event0.1 (0.01 to 0.27)
Hospitalization related to CV9.6 (8.47 to 10.75)
SecondaryPercentage of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - On Edoxaban Treatment

Descriptive statistics were used to report the number of participants with overall symptomatic VTE recurrence. VTE recurrence data were further reported by recurrent deep venous thrombosis (DVT), recurrent pulmonary embolism (PE) with deep venous thrombosis (DVT), and recurrent PE only. Recurrent VTE events were based on adjudicated events. For symptomatic VTE recurrence, percentage of participants (95% confidence intervals) were calculated.

Time frame:
Baseline up to end of observation period (18 months)
Reported as:
Number · Percentage of VTE recurrence
Percentage of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - On Edoxaban Treatment
Percentage of VTE recurrenceETNA-VTE
Recurrent VTE1.4 (0.99 to 1.92)
Recurrent DVT only1.0 (0.67 to 1.48)
Recurrent PE with DVT0 (0 to 0.21)
Recurrent PE only0.3 (0.16 to 0.65)
All-cause death1.9 (1.41 to 2.49)
CV-related death0.4 (0.21 to 0.74)
VTE-related death0 (0 to 0.21)
Stroke0.6 (0.32 to 0.93)
Systemic embolic event0 (0 to 0.21)
Hospitalization-related to cardiovascular6.3 (5.42 to 7.31)
SecondaryTotal Number of Venous Thromboembolism Recurrences By Type - Overall

Descriptive statistics were used to describe the number of VTE events reported by the patient. For VTE recurrences, absolute number of VTE events were calculated.

Time frame:
Baseline up to end of observation period (18 months)
Reported as:
Number · VTE recurrences
Total Number of Venous Thromboembolism Recurrences By Type - Overall
VTE recurrencesETNA-VTE
Total number of VTE recurrences105
Deep vein thrombosis (DVT) only64
Pulmonary embolism with DVT7
Pulmonary embolism only32
SecondaryDuration of Venous Thromboembolism Recurrences, by Type - Overall

Descriptive statistics were used to assess the duration of VTE events reported by the patient. For VTE recurrences, median duration of VTE events (interquartile range) were calculated.

Time frame:
Baseline up to end of observation period (18 months)
Reported as:
Median · days
Duration of Venous Thromboembolism Recurrences, by Type - Overall
daysETNA-VTE
Total number of VTE recurrences18.0 (8.0 to 93.0)
Deep vein thrombosis (DVT) only44.5 (8.0 to 95.0)
Pulmonary embolism with DVT8.0 (5.0 to 146.0)
Pulmonary embolism only16.0 (8.0 to 93.0)
SecondaryTotal Number of Venous Thromboembolism Recurrences (On Edoxaban Treatment)

Descriptive statistics were used to assess the number of recurrent VTE events reported by the patient. For VTE recurrences, absolute number of VTE recurrences were calculated.

Time frame:
Baseline up to end of observation period (18 months)
Reported as:
Number · VTE recurrences
Total Number of Venous Thromboembolism Recurrences (On Edoxaban Treatment)
VTE recurrencesETNA-VTE
Total number of VTE recurrences39
Deep vein thrombosis (DVT) only28
Pulmonary embolism with DVT1
Pulmonary embolism only9
SecondaryDuration of Venous Thromboembolism Events (On Edoxaban Treatment)

Descriptive statistics were used to assess the duration of VTE events reported by the patient. For VTE events, median duration of VTE events (interquartile range) were calculated.

Time frame:
Baseline up to end of observation period (18 months)
Reported as:
Median · days
Duration of Venous Thromboembolism Events (On Edoxaban Treatment)
daysETNA-VTE
Total number of VTE recurrences11.0 (8.0 to 20.0)
Deep vein thrombosis (DVT) only9.5 (8.0 to 20)
Pulmonary embolism with DVT0 (0 to 0)
Pulmonary embolism only15.0 (8.0 to 16.0)
SecondaryNumber of Participants With Risk Factors for Thromboembolic Events at Baseline

Descriptive statistics were used to assess the number of participants with risk factors for thromboembolic events. For risk factors for thromboembolic events, absolute number of participants with risk factors (percentage) were calculated.

Time frame:
at Baseline
Reported as:
Count of participants · Participants
Number of Participants With Risk Factors for Thromboembolic Events at Baseline
ParticipantsETNA-VTE
Puerperium9
Prolonged immobilisation401
>5 days in bed218
History of major surgery trauma359
Known thrombophilic conditions111
SecondaryDuration of Edoxaban Treatment

Descriptive statistics were used to report the duration of edoxaban treatment.

Time frame:
Baseline up to end of observational period (18 months)
Reported as:
Count of participants · Participants
Duration of Edoxaban Treatment
ParticipantsETNA-VTE
Month 1 ongoing2527
Month 3 ongoing2346
Month 6 ongoing1842
Month 12 ongoing1272
Month 18 ongoing713
Participants off edoxaban treatment at 18 months1910
SecondaryNumber of Stroke Events

Descriptive statistics were used to report the number of stroke events. For stroke events, absolute number of stroke events were calculated.

Time frame:
Baseline up to end of observation period (18 months)
Reported as:
Number · events
Number of Stroke Events
eventsETNA-VTE
Overall treatment: Total number of stroke events27
Overall treatment: Ischemic events17
Overall treatment: Haemorrhagic events5
Overall treatment: Unknown events5
On treatment: Total number of stroke events16
On treatment: Ischemic events12
On treatment: Haemorrhagic events3
On treatment: Unknown events1
SecondaryNumber of Systemic Embolic Events - Overall

Descriptive statistics were used to report the number of systemic embolic events (SEE). For SEE, absolute SEEs were calculated.

Time frame:
Baseline up to end of observation period (18 months)
Reported as:
Number · Systemic embolic events
Number of Systemic Embolic Events - Overall
Systemic embolic eventsETNA-VTE
Upper/lower extremity1
Renal1
SecondaryOverview of Participants With Adverse Drug Reactions

Descriptive statistics were used to report an overview of participants with adverse drug reactions (ADR). ADRs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1.

Time frame:
Baseline up to end of observation period (18 months)
Reported as:
Count of participants · Participants
Overview of Participants With Adverse Drug Reactions
ParticipantsETNA-VTE
Death due to ADR2
Participants with at least 1 ADR142
Participants with at least 1 serious ADR59
Study discontinuation due to ADR0
SecondaryNumber of Participants With Adverse Drug Reactions by Preferred Term (≥0.2%)

Adverse drug reactions were reported and coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1.

Time frame:
Baseline up to end of observational period (18 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Drug Reactions by Preferred Term (≥0.2%)
ParticipantsETNA-VTE
Haemorrhage35
Gastrointestinal haemorrhage12
Menorrhagia12
Epistaxis11
Fatigue8
Nausea8
Dizziness7
Rash7
Headache5
Pruritus5
SecondaryNumber of Participants With Pre-defined Adverse Drug Reactions

Descriptive statistics were used to report the number of participants with pre-defined adverse drug reactions (ADR). ADRs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1.

Time frame:
Baseline up to end of observation period (18 months)
Reported as:
Count of participants · Participants
Number of Participants With Pre-defined Adverse Drug Reactions
ParticipantsETNA-VTE
Stroke2
Bleeding events75
Systemic embolic events0
Non-valvular atrial fibrillation0
Malignancy0
Others4

Adverse events

Collected over Treatment-emergent adverse events were not assessed in this non-interventional (observational) study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ETNA-VTE98/2,644 (3.7%)——

Baseline characteristics

Demographic and baseline characteristics were assessed in the Full Analysis Set.

Age, Continuous
Age, Continuous(years)ETNA-VTE
Median65.0 (52.0 to 76.0)
Age, Customized
Age, Customized(Participants)ETNA-VTE
<65 years1312
≥65 and <75 years593
≥75 years739
Sex: Female, Male
Sex: Female, Male(Participants)ETNA-VTE
Female1231
Male1413
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)ETNA-VTE
Region of Enrollment
Region of Enrollment(participants)ETNA-VTE
Germany722
Austria182
Switzerland84
Belgium372
Netherlands321
United Kingdom113
Ireland17
Italy833
08

Study locations

1 site
  • International Clinical Research GmbH
    Germering, 82110, Germany
09

References and documents

Publications

  • Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19. PubMed 24251359 ↗
  • Hokusai-VTE Investigators; Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31. PubMed 23991658 ↗
  • Cohen AT, Hoffmann U, Hainaut P, Gaine S, Ay C, Coppens M, Schindewolf M, Jimenez D, Bruggenjurgen B, Levy P, Laeis P, Fronk EM, Zierhut W, Malzer T, Manu MC, Reimitz PE, Bramlage P, Agnelli G; ETNA-VTE-Europe investigators. ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. Eur J Intern Med. 2020 Dec;82:48-55. doi: 10.1016/j.ejim.2020.08.014. Epub 2020 Aug 18. PubMed 32826158 ↗
  • Cohen AT, Ay C, Hainaut P, Decousus H, Hoffmann U, Gaine S, Coppens M, da Silva PM, Castro DJ, Amann-Vesti B, Bruggenjurgen B, Levy P, Bastida JL, Vicaut E, Laeis P, Fronk EM, Zierhut W, Malzer T, Bramlage P, Agnelli G; ETNA-VTE-Europe investigators. Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study. Thromb J. 2018 May 1;16:9. doi: 10.1186/s12959-018-0163-7. eCollection 2018. PubMed 29719492 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Dec 2020, 55 months.

Results were first posted in May 2022, 1 year 5 months after primary completion.

Of 118 observational studies under Venous Thromboembolism, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 75. This study's 55 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2016
First posted
Oct 25, 2016
StartActual
Apr 6, 2016
Primary completionActual
Dec 1, 2020
CompletionActual
Dec 1, 2020
Results first posted
May 2, 2022
Last update
Apr 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02943993
Responsible party
Sponsor
First posted
Oct 25, 2016
Start date
Apr 6, 2016
Primary completion
Dec 1, 2020
Completion
Dec 1, 2020
Results posted
May 2, 2022
Last update
Apr 1, 2025

Study contacts

Global Clinical Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion